Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial
Frontiers in Medicine · 21.05.2026 · 13
DOI: 10.3389/fmed.2026.1845534 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Frontiers in Medicine, online erschienen am 21.05.2026. Verfasst von Xiangjin Gao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Health Commission Traditional Chinese Medicine Standard Research Project, China Fund for Medical Equipment, Clinical Research Program of Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) is a prevalent chronic and recurrent inflammatory skin disease. Guidelines for the treatment and care of AD suggest that appropriate bathing can facilitate the repair of skin lesions. MuShengshu is a weakly acidic bath solution that contains traditional Chinese medicine ingredients. Previous studies indicate its potential to alleviate pruritus and promote the healing of skin lesions in patients with dermatosis. However, high-quality evidence is still limited.
Objectives
This randomized, double-blind, placebo-controlled clinical trial aims to assess the efficacy and safety of MuShengshu (MSS) combined with foundational therapies in patients with mild-to-moderate AD.
Methods
A total of 66 patients with mild-to-moderate AD will be enrolled at the Shanghai Skin Disease Hospital from August 2025 to June 2026. Patients will be randomly assigned in a 2:1 ratio to either the treatment group (MSS combined with foundational therapies, n = 44) or the control group (MSS placebo combined with foundational therapies, n = 22). Patients will receive MSS or MSS placebo once daily, for 4 months. Meanwhile, the foundational therapies include desonide cream for mild AD and triamcinolone acetonide cream for moderate AD, both of which will be applied twice daily for 2 weeks. Additionally, all patients will receive urea ointment twice daily for 4 weeks. The primary outcome indicator is EASI 50 , defined as the proportion of patients achieving ≥50% improvement in the Eczema Area and Severity Index (EASI) score at week 4 from baseline. The secondary outcome indicators include the EASI, Visual Analogue Scale (VAS), Investigator’s Global Assessment (IGA), and Dermatology Life Quality Index (DLQI), which will be assessed at baseline (week 0), weeks 1, 2, 4, and 16. In this study, statistical analyses will be conducted using SAS 9.4 software, with statistical significance being defined as a two-tailed α level of 0.05.
Results
In this study, ethical approval was granted in March 2025, with registration completed in the International Traditional Medicine Clinical Trial Registry in June 2025. Recruitment of participants began in August 2025 and is anticipated to completed by June 2026. Data analysis is set to start in August 2026, with preliminary trial results expected to be submitted for peer-reviewed publication by December 2026.
Conclusion
Findings in this study are expected to provide evidence for the incorporation of traditional Chinese herbal bath solutions into the comprehensive management of AD. Clinical trial registration https://www.chictr.org.cn/ , Identifier ITMCTR2025001206.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Research Center, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China.
- School of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- School of Medicine, Tongji University, Shanghai, China.
Förderung
- Shanghai Municipal Health Commission Traditional Chinese Medicine Standard Research Project
- China Fund for Medical Equipment
- Clinical Research Program of Shanghai Municipal Health Commission
- Clinical Research Plan of SHDC
Zitieren
APA
Gao, X., Cai, R., Lu, J., Duan, Z., Xu, Q., Zhang, X., Shen, F., Zhang, R., Li, B., & Wang, R. (2026). Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1845534
Vancouver
Gao X, Cai R, Lu J, Duan Z, Xu Q, Zhang X, et al. Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1845534
BibTeX
@article{Gao2026,
author = {Gao, Xiangjin and Cai, Ruiqi and Lu, Jinrong and Duan, Zhen and Xu, Quanruo and Zhang, Xiuqi and Shen, Fanlingzi and Zhang, Rui and Li, Bin and Wang, Ruiping},
title = {Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1845534}
}
EUVIMED